Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comparative Study
. 2001 Jun;45(6):1915-8.
doi: 10.1128/AAC.45.6.1915-1918.2001.

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers

P C Fuchs  1 , A L Barry, S D Brown
Affiliations
Comparative Study

In vitro activities of ertapenem (MK-0826) against clinical bacterial isolates from 11 North American medical centers

P C Fuchs et al. Antimicrob Agents Chemother. 2001 Jun.

Abstract

This study compared the in vitro activities of the new long-half-life carbapenem ertapenem (also known as MK-0826 and L-749,345) with those of imipenem, amoxicillin-clavulanate, and ciprofloxacin against 5,558 recent clinical isolates from 11 North American medical centers. We confirmed the greater activity of ertapenem than of imipenem against the Enterobacteriaceae and the greater activity of imipenem against pseudomonads and gram-positive bacteria.

PubMed Disclaimer

References

    1. Fuchs P C, Barry A L, Brown S D. In-vitro antimicrobial activity of a carbapenem, MK-0826 (L-749,345) and provisional interpretive criteria for disc tests. J Antimicrob Chemother. 1999;43:703–706. - PubMed
    1. Gill C J, Jackson J J, Gerckens L S, Pelak B A, Thompson R K, Sundelof J G, Kropp H, Rosen H. In vitro activity and pharmacokinetic evaluation of a novel long-acting carbapenem antibiotic, MK-826 (L-749,345) Antimicrob Agents Chemother. 1998;42:1996–2001. - PMC - PubMed
    1. Jacoby G, Han P, Tran J. Comparative in vitro activities of carbapenem L-749,345 and other antimicrobials against multiresistant gram-negative clinical pathogens. Antimicrob Agents Chemother. 1997;41:1830–1831. - PMC - PubMed
    1. Kohler J, Dorso K L, Young K, Hammond G G, Rosen H, Kropp H, Silver L L. In vitro activities of the potent, broad-spectrum carbapenem MK-0826 (L-749,345) against broad-spectrum β-lactamase- and extended-spectrum β-lactamase-producing Klebsiella pneumoniae and Escherichia coli clinical isolates. Antimicrob Agents Chemother. 1999;43:1170–1176. - PMC - PubMed
    1. National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, 4th ed. Approved standard M7–A4. Wayne, Pa: National Committee for Clinical Laboratory Standards; 1997.

Publication types

MeSH terms